Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. announced inducement grants to recently hired employees on May 18, 2026, including stock options for one employee and restricted stock units (RSUs) for seven employees. These grants, made under the company's 2021 Inducement Equity Incentive Plan, serve as a material inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants feature four-year vesting schedules for both the stock options and RSUs.
Schrodinger (SDGR) Issues Stock Options and RSUs to New Employees
Schrodinger Inc (SDGR) has announced the issuance of stock options and restricted stock units (RSUs) to new employees as part of its talent attraction and retention strategy. This move, compliant with Nasdaq Listing Rules, involved granting options for 1,875 shares and RSUs for 18,766 shares that vest over four years. While the company exhibits strong growth potential with a GF Score of 66/100, concerns exist regarding its profitability, financial strength, and recent insider selling of $1.3 million.
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Schrödinger (SDGR) announced inducement grants in compliance with Nasdaq Listing Rule 5635(C)(4). The grants were reported by Refinitiv and are part of the company's regulatory disclosures. The article is very brief and directs readers to log in for more details.
Schrodinger reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Schrodinger, Inc. has reported inducement grants under Nasdaq Listing Rule 5635(c)(4). The company develops a physics-based computational platform for drug discovery and materials applications, operating through Software and Drug Discovery segments. This news follows several other recent updates for Schrodinger, including earnings calls and analyst rating changes.
SDGR: Improved funding and tech adoption are accelerating drug discovery and portfolio growth
Schrodinger, Inc. (SDGR) is experiencing accelerated drug discovery and portfolio growth due to improved funding in biotech and pharma, leading to new customer acquisition and increased technology adoption. The company is leveraging early-stage computational tools, predictive toxicology, and its upcoming Bunsen AI platform to enhance productivity. Strong financial outlook is supported by proprietary assets and strategic partnerships.
Schrodinger : SDGR
This article provides an overview of Schrodinger Inc. (SDGR), a company focused on developing a computational platform for drug development and materials science. It highlights their business model, stock data, and lists recent articles related to healthcare AI stocks and growth opportunities in AI, some of which feature Schrodinger.
Schrodinger : SDGR
Schrodinger Inc (SDGR) is a company that develops a computational platform for accelerated drug discovery and materials applications. It licenses its software and is also involved in its own drug discovery programs and partnerships. The article also lists recent news and articles related to the company and the broader market.
Schrodinger stock (US80655G1067): AI-powered drug discovery story after latest earnings
Schrodinger, a company combining computational chemistry, AI, and drug discovery, recently released its latest quarterly figures. The article highlights the company's dual business model, comprising a recurring software segment and a drug discovery segment, and analyzes its revenue drivers, competitive landscape, and significance for US investors. It also discusses the challenges and opportunities presented by this hybrid structure.
Rubric Capital and David Rosen disclose 9.28% position in Schrodinger (SDGR)
Rubric Capital Management and David Rosen have disclosed a 9.28% beneficial ownership stake in Schrodinger, Inc. (SDGR), totaling 6,000,000 shares. This disclosure, made via an amended Schedule 13G/A filing dated May 15, 2026, indicates a passive investment intent with shared voting and dispositive power. The percentage is based on 64,660,908 shares outstanding as of February 18, 2026.
SDGR Price Today: Schrodinger, Inc. Stock Price, Quote & Chart | MEXC
This article provides details on Schrodinger, Inc. (SDGR) stock price and performance as of May 15, 2026. It highlights the current trading price, recent fluctuations, and key market data such as market cap, open, high, low, and volume. Additionally, it offers information on how to buy SDGR stock through MEXC and provides an overview of the company's business model and financial metrics.
(SDGR) Movement as an Input in Quant Signal Sets
This article analyzes Schrodinger Inc. (NASDAQ: SDGR) using AI models, identifying near-term weak sentiment but mid-term strength. It presents three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 79.3:1 risk-reward setup targeting a 20.1% gain.
SDGR Maintained by Morgan Stanley -- Price Target Lowered to $17
Morgan Stanley analyst Vikram Malhorta has reiterated an Equal-Weight rating for Schrodinger (SDGR) but lowered its price target from $19.00 to $17.00. Despite this, GuruFocus indicates SDGR is 52.6% undervalued, with a GF Value™ of $26.90 compared to its current price of $12.74, suggesting a potential margin of safety for investors. However, insider activity shows a $1.3 million sell-off in the last three months, raising a cautious flag for potential "value trap."
Morgan Stanley Lowers Price Target on Schrodinger to $17 From $19, Keeps Equalweight Rating
Morgan Stanley has lowered its price target for Schrodinger (SDGR) from $19 to $17, while maintaining an "Equalweight" rating on the stock. This adjustment comes despite recent positive news for Schrodinger, including Q1 2026 earnings exceeding analyst estimates and presentations at healthcare conferences. The report also highlights that Schrodinger's shares are currently trading at $12.62, significantly below the average target price of $20.88 set by analysts.
Schrodinger, Inc. Stock 12‑Month Price Target Cut to $20.88, Implies 64% Upside
The 12-month average price target for Schrodinger, Inc. (SDGR) stock has been slightly reduced from $21.12 to $20.88 by 8 analysts. This new target suggests a potential upside of approximately 64% from its May 13 closing price. The consensus rating for the stock remains a "Buy," with 6 analysts recommending a Buy and 2 recommending a Hold.
SDGR: Hosted revenue jumps to 34% as broad-based growth and new products drive positive momentum
Schrodinger, Inc. (SDGR) reported Q1 results that surpassed guidance, driven by broad-based growth, increased adoption of hosted revenue solutions, and successful new product introductions. The company is on track with its transition to hosted solutions, aiming for 75% adoption by 2028 with minimal resistance. This positive momentum, supported by innovations in predictive toxicology and AI, underpins a favorable outlook and profitability targets.
UBS Group AG Buys 489,059 Shares of Schrodinger, Inc. $SDGR
UBS Group AG significantly increased its stake in Schrodinger, Inc. (SDGR) by 51.3% in the fourth quarter, purchasing 489,059 additional shares, bringing its total holdings to 1,442,799 shares valued at approximately $25.8 million. Other institutional investors also raised their positions, with institutional ownership now at 79.05%. Despite missing quarterly EPS estimates, Schrödinger's revenue exceeded expectations, and analysts currently rate the stock as a "Hold" with a $20.50 price target.
Number of shareholders of Schrodinger, Inc. – LS:A2PY7M
This page from TradingView provides an overview of Schrodinger, Inc. (A2PY7M), a company listed on the Lang & Schwarz Tradecenter. The primary content of the article is a heading indicating information about the number of shareholders for Schrodinger, Inc., although the specific value and change data are not displayed in the provided text. The page appears to be a stub or placeholder from a financial data platform.
Schrodinger Inc stock (US80655G1067): Q1 loss and revenue miss weigh on shares
Schrodinger Inc reported a wider net loss and missed revenue estimates for the first quarter of 2026, causing its Nasdaq-listed stock to decline. The company's core business involves a computational-drug-discovery platform, combining physics-based simulations with machine learning for drug design. Despite its technological promise, the financial results underscore challenges in achieving consistent top-line growth and profitability for this pre-profitability growth company.
Analysts Have Lowered Expectations For Schrödinger, Inc. (NASDAQ:SDGR) After Its Latest Results
Analysts have lowered their revenue and increased their loss per share expectations for Schrödinger, Inc. (NASDAQ:SDGR) following its latest quarterly results, despite revenues exceeding forecasts. While the stock price increased, the consensus revenue forecast for 2026 implies an 8.3% decline, and losses are projected to balloon. The average price target remains unchanged, suggesting analysts might view the weaker short-term outlook as not impacting long-term valuation.
Analysts Have Lowered Expectations For Schrödinger, Inc. (NASDAQ:SDGR) After Its Latest Results
Analysts have lowered their revenue and increased loss per share expectations for Schrödinger, Inc. (NASDAQ:SDGR) following its latest quarterly results. Despite reporting higher-than-expected revenues, statutory losses significantly ballooned, leading to a revised outlook suggesting an 8.3% revenue decline in 2026 and a 51% increase in projected losses per share. The average price target remained steady, indicating that the weaker earnings outlook might not have a long-term impact on the valuation, but the company's revenue growth is expected to underperform the wider industry.
Schrödinger Reports First Quarter 2026 Financial Results
Schrödinger Inc. announced its first-quarter 2026 financial results, reporting strong growth in ACV and drug discovery revenue, with ACV up 12% to $28.4 million. The company is transitioning to hosted software licensing and plans to release "Bunsen," an agentic AI co-scientist, this summer. The acquisition of co-founded Ajax Therapeutics by Lilly for up to $2.3 billion validates Schrödinger's platform and collaboration model.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger (SDGR) has reported inducement grants under Nasdaq Listing Rule 5635(c)(4). This announcement was delivered via Quantisnow, a real-time market data and news platform. The company, which is in the Health Care sector, also has recent analyst ratings from firms like BofA Securities, Goldman, and Citigroup, and has had several SEC filings and press releases recently.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) reported a Q1 loss of $0.81 per share, missing the Zacks Consensus Estimate of a $0.56 loss, and generated revenues of $58.59 million, falling short of the $59.55 million consensus. Despite underperforming the market year-to-date, the company has surpassed EPS estimates three out of the last four quarters and revenue estimates three times in the same period. The stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.
Schrödinger, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SDGR) 2026-05-06
Schrödinger, Inc. (SDGR) published its Q1 2026 earnings call presentation, reporting an EPS of -$0.62, missing estimates by $0.05. However, the company's revenue of $58.59 million beat expectations by $10.95 million, despite a slight year-over-year decrease of 1.62%. The slide deck accompanies their financial results for the quarter ended May 5, 2026.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Inc. (SDGR) has reported inducement grants under Nasdaq Listing Rule 5635(c)(4). This information was delivered by Quantisnow, a real-time market data platform that aggregates various financial news and SEC filings for retail investors. The article also provides recent analyst ratings and related SEC filings for Schrödinger.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) reported a wider-than-expected loss for the first quarter, posting a loss of $0.62 per share against an estimated loss of $0.56 per share. The company also significantly missed revenue estimates, bringing in $30.82 million compared to an expected $41.87 million. The stock price declined following the announcement, reflecting investor concerns over the financial performance.
Earnings call transcript: Schrödinger misses EPS but beats revenue in Q1 2026
Schrödinger Inc. (SDGR) reported mixed Q1 2026 earnings, missing EPS expectations at -$0.81 against a forecast of -$0.64, but exceeding revenue forecasts with $58.6 million. Despite a slight stock decline, drug discovery revenue grew 124% year-over-year, and the company is making progress in transitioning to hosted software licensing and launching its new AI co-scientist, Bunsen. Schrödinger reaffirmed its full-year 2026 guidance, focusing on long-term growth and operational efficiency while exploring partnerships for its therapeutic programs.
Schrödinger tees up AI drug-discovery tool as Ajax sale hits $2.3B
Schrödinger (Nasdaq: SDGR) reported strong first-quarter 2026 results with a 12% increase in Annual Contract Value (ACV) and significant growth in drug discovery revenue, while reaffirming its full-year 2026 financial outlook. The company announced plans to release "Bunsen," an agentic AI co-scientist, this summer, and highlighted the $2.3 billion acquisition of its co-founded company, Ajax Therapeutics, by Lilly, validating Schrödinger's computational platform. Additionally, Schrödinger's therapeutics portfolio showed progress with its MALT1 and Wee1/Myt1 inhibitors, with SGR-1505 receiving FDA Fast Track and Orphan Drug Designations for Waldenström macroglobulinemia.
Schrödinger (SDGR) Q1 2026 Earnings Transcript
Schrödinger reported a strong start to 2026 with a 12% increase in Annual Contract Value (ACV) to $28.4 million and total revenue of $58.6 million, driven by software growth and drug discovery revenue. The company highlighted Eli Lilly's acquisition of Ajax Therapeutics, in which Schrödinger holds a 6% equity stake, as a significant financial event, and announced the upcoming launch of Bunsen, an agentic AI co-scientist, to enhance productivity and customer workflows. Despite a net loss of $60 million and a decrease in software gross margin due to a planned transition to hosted licensing, Schrödinger maintained its full-year 2026 ACV guidance and expects operating expenses to decrease, focusing on partnerships for clinical programs.
Earnings Flash (SDGR) Schrodinger, Inc. Reports Q1 Revenue $58.6M, vs. FactSet Est of $47.6M
Schrodinger, Inc. (SDGR) reported its Q1 revenue of $58.6 million, significantly exceeding FactSet's estimated $47.6 million. The company, which operates a physics-based computational platform for drug discovery and materials science, disclosed these results along with its Q1 2026 earnings call details. This positive earnings flash highlights the company's strong performance against analyst expectations.
Schrödinger (NASDAQ: SDGR) posts Q1 2026 $58.6M revenue, keeps outlook
Schrödinger (NASDAQ: SDGR) reported Q1 2026 revenue of $58.6 million, a 2% decrease year-over-year, while reaffirming its full-year 2026 financial guidance. The company saw a 12% increase in Annual Contract Value (ACV) to $28.4 million and a significant rise in drug discovery revenue, though software revenue declined as it transitions to hosted licensing. Schrödinger also highlighted the upcoming launch of its AI co-scientist "Bunsen" and the up to $2.3 billion sale of co-founded Ajax Therapeutics, in which it held a 5.8% equity stake.
Can Schrödinger’s (SDGR) AI-Hosted Push Recast Its Investment Story Beyond Drug Discovery Hype?
Schrödinger, Inc. (SDGR) recently announced its Q1 2026 results and plans to emphasize its AI-enabled computational platform and hosted software model at upcoming investor conferences. The company aims to shift 75% of software contracts to hosted models within three years, targeting 10-15% annual contract value growth. The investment narrative hinges on the platform's ability to drive software demand and drug discovery partnerships, despite the company currently being unprofitable and relying on a concentrated customer base.
Liquidity Mapping Around (SDGR) Price Events
Stock Traders Daily provides a liquidity mapping analysis for Schrödinger Inc. (NASDAQ: SDGR), indicating divergent sentiment across horizons and a mid-channel oscillation pattern. The report outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. Key findings suggest positive near-term sentiment with a broader weak alignment, highlighting an exceptional risk-reward setup targeting a 19.5% gain.
Schrödinger to Participate in Upcoming Investor Conferences
Schrödinger, Inc. announced its participation in two upcoming investor conferences in May: the BofA Securities 2026 Healthcare Conference and the RBC 2026 Global Healthcare Conference. Management will hold fireside chats at both events. Live discussions will be available on Schrödinger’s website and archived for 90 days.
Schrödinger to Participate in Upcoming Investor Conferences
Schrödinger, Inc. announced its participation in two upcoming investor conferences in May 2026. Management will hold fireside chats at the BofA Securities 2026 Healthcare Conference on May 13 and the RBC 2026 Global Healthcare Conference on May 19. Live discussions will be accessible via Schrödinger’s website and archived for approximately 90 days.
Schrödinger will webcast two healthcare conference talks in May
Schrödinger, Inc. (Nasdaq: SDGR) announced that its management will participate in two upcoming healthcare conferences in May 2026. The company will be featured in a fireside chat at the BofA Securities 2026 Healthcare Conference on May 13th and another at the RBC 2026 Global Healthcare Conference on May 19th. Both discussions will be available via live webcast and archived on Schrödinger's investor website.
Insider sales reported for SDGR (NASDAQ: SDGR) including 752/775/608 shares
A Form 144 filing for Schrodinger, Inc. (NASDAQ: SDGR)reported proposed sales of common stock by an insider, Jenny Herman. The filing details sales of 752 shares on February 10, 2026, 775 shares on March 5, 2026, and 608 shares on March 6, 2026, with corresponding dollar amounts. The document also references a restricted stock vesting date of April 30, 2026, and lists Fidelity Brokerage Services LLC as the broker.
3.19M-share disclosure by Schrodinger (NASDAQ: SDGR) shows a 4.9% stake
Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have revealed a shared beneficial ownership of 3,190,837 shares of Schrodinger (NASDAQ: SDGR) common stock, representing a 4.9% stake. This information comes from an amended Schedule 13G/A filing, indicating a passive investment rather than any intent to control the company. The disclosure details shared voting and dispositive power over these shares, with the filing signed on April 30, 2026, and referencing data as of March 31, 2026.
Vanguard Portfolio Management (SDGR) holds 3.91M shares, 6.04% stake
Vanguard Portfolio Management has reported a 6.04% stake in Schrodinger Inc. (SDGR), holding 3,911,087 shares as of March 31, 2026. This Schedule 13G filing indicates a passive beneficial ownership, with Vanguard exercising sole dispositive power over all shares but sole voting power over only 48,890 shares. The disclosure clarifies that these holdings are part of Vanguard funds and client accounts.
AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, Chemaxon - Global Forecast to 2030 and 2035
The AI in predictive toxicology market is expected to grow significantly, reaching $2.29 billion by 2030 from $0.83 billion in 2026, driven by increased AI adoption, cloud platforms, and genomics integration. Key players like Certara Inc. and Schrodinger Inc. are leading advancements in chemical safety assessments and drug toxicity prediction. North America currently dominates the market, with Asia-Pacific showing the fastest growth potential.
Schrodinger (SDGR) Projected to Post Quarterly Earnings on Tuesday
Schrodinger (SDGR) is anticipated to announce its Q1 2026 earnings on Tuesday, May 5th, with analysts projecting a loss of ($0.56) per share and revenue of $51.23 million. The company's stock is currently trading near $12.26, and insiders have been net sellers, with CEO Ramy Farid selling 43,000 shares. Analyst coverage is mixed, holding an average "Hold" rating and a target price of $20.50.
[ARS] Schrodinger, Inc. SEC Filing
This article reports on an ARS SEC filing by Schrodinger, Inc. (SDGR) on April 28, 2026. The filing has a low impact and neutral sentiment. The article also provides an overview of SDGR's stock performance, recent news, and other SEC filings.
Form DEFA14A Schrodinger, Inc.
Schrödinger, Inc. has filed a Definitive Additional Materials proxy statement (Form DEFA14A) with the U.S. Securities and Exchange Commission. The filing concerns information required by Section 14(a) of the Securities Exchange Act of 1934 and indicates that no filing fee was required. This document is part of the regulatory disclosures for the company.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Inc. has reported inducement grants made under Nasdaq Listing Rule 5635(c)(4). This information was disseminated via Quantisnow, a platform providing real-time market data and news for investors. The article also highlights recent analyst ratings for Schrödinger (SDGR).
How many employees work at Schrodinger?
Schrödinger, Inc. currently has 974 employees, experiencing a -6.0% year-over-year growth rate as of December 2025. The company's workforce has fluctuated, with 967 employees in 2025, down from 1,027 in 2024, but up from 1,006 in 2023. Schrödinger's platform aids biopharmaceutical, industrial, academic, and government research globally, with an average employee salary of $143.9k and tenure of 3.9 years.
Schrodinger, Inc. (NASDAQ:SDGR) Given Average Recommendation of "Hold" by Brokerages
Nine brokerages have collectively given Schrodinger, Inc. (NASDAQ:SDGR) an average "Hold" recommendation, with price targets ranging from $13 to $20. Recent analyst actions include UBS Group cutting its target to $13 and KeyCorp lowering its objective to $20. The company's CEO, Ramy Farid, recently sold 43,000 shares, and Schrodinger reported mixed financials with quarterly EPS beating estimates but remaining unprofitable with a negative net margin.
Schrödinger to Announce First Quarter 2026 Financial Results on May 5
Schrödinger, Inc. (Nasdaq: SDGR) will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results. The webcast will be available in the "Investors" section of Schrödinger’s website.
Schrodinger, Inc. (SDGR) CEO exercises options and sells 86,000 shares
Schrodinger, Inc. (SDGR) CEO Ramy Farid exercised stock options to acquire 160,527 shares and subsequently sold 86,000 shares of common stock. These transactions were executed under a pre-established Rule 10b5-1 trading plan. After the sales, Farid retains a substantial equity stake, including unvested RSUs, aligning his interests with the company's long-term performance.
Schrodinger Inc Targets Software Contract Shift to Hosted Cloud Models
Schrodinger Inc. announced a strategic shift to move 75% of its software contracts to hosted cloud models within three years to meet increasing customer demand for cloud-integrated solutions. The company is collaborating with AI developers like Anthropic and partners such as Eli Lilly to enhance its AI-powered drug discovery tools. Despite a slight revenue decline, Schrodinger surpassed analyst expectations in Q4 2025, driven by a significant increase in drug discovery revenue.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 17, 2026
Schrödinger, Inc. announced on April 17, 2026, that it granted restricted stock units (RSUs) to four new employees on April 16, 2026. These grants, totaling 4,253 shares, were made under the company's 2021 Inducement Equity Incentive Plan as a material inducement for employment, aligning with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with 25% vesting after 12 months and the remainder in equal yearly installments over the subsequent three years.
